Bill Gates Discusses AI in Indonesia, OpenAI's New Health Dataset, and More - Life AI Weekly #17

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in AI within the healthcare and life sciences sectors. This week, we're spotlighting several significant developments, including Phenomix Sciences and Mayo Clinic using AI to predict side effects of GLP-1 medications, and OpenAI collaborating with the FDA to explore AI's role in drug approval processes through their new initiative, cderGPT. Additionally, the Global Ovarian Cancer Research Consortium has teamed up with Microsoft to launch a $1 million grant aimed at advancing ovarian cancer research.

In the biotech realm, Benchling and Moderna are expanding their AI collaboration, while Bioheaven360 has launched a new AI genomics platform. Meanwhile, QuantHealth has introduced a pharmaco-clinical model to enhance AI applications in life sciences. These stories highlight the ongoing integration of AI technologies in healthcare, promising to reshape the landscape of medical research and treatment.

Inductive Bio has raised $25 million in Series A funding to advance its AI platform for small molecule drug discovery, with backing from investors like Obvious Ventures and Andreessen Horowitz. Zilia Inc. has closed a bridge financing round with new investor Linearis Ventures and existing shareholders to commercialize its AI-driven Zilia Ocular™ device. ACTO Technologies, Inc. has appointed Lori Tierney, former President of Johnson & Johnson Vision, to its Board of Directors to support its AI-first platform initiatives.

Phenomix Sciences and Mayo Clinic have developed a machine-learning algorithm to predict nausea in patients using GLP-1 therapies. OpenAI and the FDA are discussing the use of AI in drug approval with the cderGPT project. The Global Ovarian Cancer Research Consortium and Microsoft announced a $1 million grant for AI research in ovarian cancer. QuantHealth launched its Pharmaco-Clinical Model to enhance drug effectiveness predictions. The FDA plans to deploy AI by June 2025 to modernize drug approval processes.

Benchling announced an expanded collaboration with Moderna to enhance AI-driven research and development, aiming to unify scientists on a digital platform for biotech innovation. Bioheaven360 has launched an AI-powered genomics diagnostics platform for early disease detection and personalized treatment, developed with AIIMS. Researchers at the Centre for Genomic Regulation have used AI to create synthetic enhancers that influence gene expression, aiding in blood stem cell differentiation for gene therapy.

Bill Gates met with Indonesian President Prabowo Subianto to discuss AI's role in health, education, and agriculture. HighPeak launched an AI platform for healthcare cost forecasting. Trella Health appointed David Kerr as CTO to lead its technology vision.